FDAnews
www.fdanews.com/articles/143088-merck-hepatitis-c-drug-may-ldquo-anchor-rdquo-future-worldwide-regimen

Merck Hepatitis C Drug May “Anchor” Future Worldwide Regimen

January 10, 2012
Merck will make whatever deals are necessary to ensure the company leads the race for future hepatitis C combination therapies, said Roger Pomerantz, the drugmaker’s worldwide head of licensing and acquisitions.
Bloomberg